-
Mashup Score: 23Stool Microbiome Signature Associated with Response to Neoadjuvant Pembrolizumab in Patients with Muscle-invasive Bladder Cancer - 4 month(s) ago
Using preimmunotherapy stool samples collected from patients enrolled in the PURE-01 clinical trial, testing neoadjuvant pembrolizumab in patients with muscle-invasive bladder cancer, we identified some bacterial taxa that were enriched differentially in responders and nonresponders to immunotherapy. Among those, the genus Sutterella was enriched in responders, while the species Ruminococcus bromii was enriched in nonresponders. We further used an animal model of bladder cancer to provide further evidence suggesting a negative role of R. bromii in anti–PD-1 efficacy. However, further studies are needed to confirm our findings.
Source: www.europeanurology.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 8VI‐RADS use predicting the outcome of neoadjuvant pembrolizumab in muscle‐invasive bladder cancer - 7 month(s) ago
Purpose To evaluate the predictive capability of the pre- and post-pembrolizumab vesical imaging–reporting and data system (VI-RADS) to identify ypT0N0 or ypT≤1N0 response in muscle-invasive bladder…
Categories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0
The response to checkpoint immunotherapy within bladder cancer patients is highly variable. Here, the authors use RNA-seq, ATAC-seq and digital spatial profiling of pre- and post-treatment samples from the PURE01 trial to identify subtypes associated with treatment response.
Source: NatureCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 3
Abstract. Purpose: The PURE-01 study (NCT02736266) pioneered the neoadjuvant immune-checkpoint inhibitor (ICI) therapy before radical cystectomy (RC) in patients with muscle-invasive urothelial bladder carcinoma (MIBC). We herein present the survival outcomes after a median follow-up of three years. Patients and methods: The intention-to-treat (ITT) population included 155 patients. Event-free…
Categories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 1
AUA 2022 outcomes results of PURE-01, an open-label, single-arm, phase 2 study, where cT2-4aN0M0 MIBC patients received three courses of 200 mg pembrolizumab preceding radical cystectomy.
Source: www.urotoday.comCategories: General Medicine News, Latest HeadlinesTweet-
Neoadjuvant pembrolizumab may result in long-term outcome improvement in biomarker-unselected patients with #MIBC: Updated results from #PURE01. Presented by Luigi Nocera, MD @SanRaffaeleMI. #AUA22 written coverage by @rksayyid @mcg_urology on UroToday > https://t.co/fUon5gtLLI https://t.co/6D0KbtkNmF
-
-
Mashup Score: 1The Paradoxical Role of Body Mass Index in Patients with Muscle-invasive Bladder Cancer Receiving Neoadjuvant Immunotherapy - 2 year(s) ago
Elevated body mass index (BMI) is an established risk factor for many malignancies [1]. However, among patients with advanced disease, high BMI has been associated with better overall prognosis, a phenomenon known as the obesity paradox [2–5]. In the context of immunotherapy, previous studies on melanoma, lung cancer, and renal cell carcinoma have demonstrated a survival advantage for patients…
Source: European Urology OncologyCategories: Latest Headlines, UrologyTweet
-
Mashup Score: 1
AUA 2021 PURE-01 trial assessing the association between continence recovery (CR) and mpMRI, robot-assisted radical cystectomy (RARC) with orthotopic bladder reconstruction (OBR), urinary diversion, ileal conduit or orthotopic bladder reconstruction (OBR) with a neobladder.
Source: www.urotoday.comCategories: General Medicine News, Latest HeadlinesTweet-
Pre-surgical multiparametric MRI features predicting #continence after robotic radical cystectomy with orthotopic #bladder reconstruction: preliminary findings from #PURE01. Presented by @ManuelaTutolo @SanRaffaeleMI. #AUA21 written coverage > https://t.co/GuVWX1C9UP @WallisCJD https://t.co/u4kT01WsLn
-
-
Mashup Score: 0
DOI: 10.1200/JCO.21.00330 Journal of Clinical Oncology 39, no. 12 (April 20, 2021) 1311-1313. Published online March 18, 2021. PMID: 33734809
Source: Journal of Clinical OncologyCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 4
Clinical high-grade (HG) T1 non-muscle invasive bladder cancer (NMIBC) represents a significant risk to patients, but these patients are not typically…
Source: www.sciencedirect.comCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 8Neoadjuvant immunotherapy is reshaping cancer management across multiple tumour types: The future is now! - 3 year(s) ago
The Italian Network for Tumor Biotherapy (Network Italiano per la Bioterapia dei Tumori [NIBIT]) Foundation hosted its annual 2020 Think Tank meeting …
Source: www.sciencedirect.comCategories: Hem/Oncs, Latest HeadlinesTweet
💣 Stool Microbiome Signature Associated w Response to Neoadj Pembro in pts with MIBC #PURE01 Congrats to the entire team pursuing knowledge from this trial @SanRaffaeleMI @MyUniSR @Pederfizzo @EUplatinum https://t.co/doRk0Gdjxx